天辰生物IPO：两年半亏掉3亿，估值5年狂飙至20亿，创始人89岁高龄任执行董事

Core Viewpoint - Tianchen Biopharmaceutical (Suzhou) Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, focusing on antibody drugs for autoimmune and inflammatory diseases, but has not yet commercialized any products [1][12]. Financial Performance - Over the past two and a half years, the company has incurred cumulative losses of 327 million yuan, with research and development expenses consistently accounting for over 70% of these losses [3][14]. - The financial data shows losses of approximately 95.78 million yuan in 2023, 137.32 million yuan in 2024, and 94.21 million yuan in the first half of 2025, indicating an expanding loss trend [4][15]. - The company’s cash flow from operating activities has also been negative, with net cash flows of -60.87 million yuan, -104 million yuan, and -47.67 million yuan during the same periods [15]. Capital Operations - Since its establishment in 2020, the company has rapidly increased its valuation from several hundred million yuan to over 2 billion yuan through multiple rounds of financing [1][16]. - The company completed several financing rounds, including B2 and B3 rounds, which raised its valuation from 1.31 billion yuan to 2.008 billion yuan in a short period [6][16]. Product Pipeline - The company’s product pipeline is heavily focused on two core products, LP-003 and LP-005, with LP-003 currently in Phase III clinical trials for allergic rhinitis and expected to submit a Biologics License Application (BLA) by the third quarter of 2026 [10][20]. - Both products are still in early clinical stages for other indications, indicating a long path to commercialization [20]. Governance and Management - The company’s co-founder, Dr. Sun, aged 89, has been a board member since 2020 and will transition to an executive director role in 2025, raising concerns about the management team's age structure and talent succession [2][13]. - The company is involved in a technical contract dispute, which is set to be heard in court between 2023 and 2024 [18][19]. Supply Chain Concentration - The company’s supply chain is showing increasing concentration, with the top five suppliers accounting for 48.58%, 51.65%, and 57.93% of total procurement from 2023 to the first half of 2025 [11][21]. - This concentration poses risks related to the stability of supply, price fluctuations, and quality control, which are critical for a biotech company in its early stages [21].